Annals publishes 12-month OSPREY trial data for LivaNova sleep apnea device

• LivaNova disclosed publication of 12-month results from OSPREY randomized controlled trial in Annals of Internal Medicine, following previously released top-line data in May 2025.
• Study showed proximal hypoglossal nerve stimulation delivered by aura6000 System improved obstructive sleep apnea outcomes versus control, with benefits sustained through 12 months of therapy.
• Safety profile was described as acceptable, with no serious device-related adverse events reported in trial.
• Company noted it received FDA premarket approval for aura6000 based on OSPREY’s primary endpoints at six months of treatment.
• LivaNova targets independent commercialization of its obstructive sleep apnea product in 2027, pending FDA review of a next-generation device supplement designed to add MRI compatibility, remote configuration management, and a rechargeable battery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260420009513) on April 20, 2026, and is solely responsible for the information contained therein.